Warscheid Lab - Targeted FLNc S2233 S2236 phosphorylation assay

Warscheid Lab - Targeted FLNc S2233 S2236 phosphorylation assay
Targeted FLNc S2233 S2236 phosphorylation assay
  • Organism: Homo sapiens, Mus musculus
  • Instrument: Q Exactive Plus
  • SpikeIn: Yes
  • Keywords: FLNc, phosphoproteomics, PRM assay
  • Submitter: Lena Reimann
Abstract
In FLNc 10 phosphosites in FLNc (including S2234, S2237 and T2239) were found to be differentially phosphorylated. FLNc-pS2234 was by far the most abundant phosphosite followed by pS2237, while levels of FLNc-pT2239 were very low. pS2234 and pS2237 are part of the extended basophilic motif which is located in Ig-like domain 20 (d20)of FLNc. While levels of pS2234 and pS2234/pS2237 were strongly reduced following inhibition of PI3K/Akt signaling and increased upon IGF1-mediated stimulation, the levels were reversed for pS2237. This suggests that concurrent phosphorylation of FLNc at S2234 and S2237 prevails in vivo with pS2234 being the main site regulated by PI3K/Akt. In vitro kinase assays coupled to LC-MS (n=4) confirmed hFLNC-S2233 as prominent substrate site of Akt, while PKC alpha preferentially phosphorylateds S2236 in vitro. Accordingly, incubation with both kinases led to an increase of the doubly phosphorylated (pS2233 and pS2236) form. To validate these findings in myocytes, we performed an in cellulo kinase assays with pharmacologic interventions using Gö6976, PMA, IGF.1 and MK-2206, respectively, or a combination of the two inhibitors with PMA and IGF-1 followed by targeted MS analysis.
Experiment Description
Mouse C2 cells transiently expressing BirA* FLNc d18-21 were treated for 1 h with 10 µM MK-2206 (Selleck) or 10 µM Gö6976 (Merck) for 1 h or with 300 nM PMA (Sigma Aldrich) or IGF-1 (sigma Aldrich) for 15 min. In experiments using both, inhibitor and activator, cells were first treated with the respective inhibitor (MK-2206, Gö6976) for 1 h and PMA or IF-1 was added for the last 15 min of the treatment. Cells were lysed on ice with 500 µl modified RIPA buffer. Enrichment of the Myc-tagged FLNc fragment was performed with 10 µl Myc-Dynabeads (Invitrogen) according to the manufacturer’s protocol. On-bead tryptic digestion was performed in 200 µl ammonium bicarbonate solution (50 mM) for 3.5 h at 42°C and 1,400 rpm on a thermoshaker using sequencing grade trypsin,(Promega) in a 1:50 (w/w) ratio. Phosphopeptides were enriched as described above and mixed with 47.5-95 fmol phosphopeptides of a phosphopeptide standard comprising 181 phosphopeptides (Intavis). For targeted MS analysis on a QExactive Plus instrument, an inclusion list comprising 40 different precursor masses was generated with Skyline 2.6.0.6709. One scan cycle consisted of a full MS1 scan at a resolution of 70,000, an automatic gain control (AGC) target of 3e6 ions, a max. ion time of 20 ms and a scan range from m/z 400 to 1600, followed by 10 PRM scans. Each PRM scan targeted one precursor of the inclusion list at a resolving power of 17,500, an AGC target of 2e5, a max. ion time of 49 ms and an isolation window of 2 m/z. Raw files were analyzed with Skyline and intensities of hFLNc phosphopeptides were normalized to the summed intensities of eight phosphopeptides (SEGpSPVLPHEPAK, TGMGSGpSAGKEGGPFK, pSTVASMMHR, VIEDNEpYTAR, LIEDNEpYTAR, pSFNGSLKNVAVDELSR, pSGGQRHSPLSQR, AYpTHQVVTR) from the standard under control conditions.
Created on 3/4/20, 1:17 PM
Clustergrammer Heatmap
 
Download
TPAD_CSF3A_Batch5-multiNF-DIANN.sky.zip2025-06-30 15:31:332,85327,12832,575259,53243
TPAD_CSF3A_Batch5-multiNF-DIANN-grouped.sky.zip2025-06-30 15:23:252,67226,43931,769253,11943
TPAD_CSF3B_Batch6-multiNF-DIANN.sky.zip2025-06-30 14:43:542,85327,12832,575259,53241
TPAD_CSF3B_Batch6-multiNF-DIANN-grouped.sky.zip2025-06-30 14:36:142,67226,43931,769253,11941
TPAD_CSF4_Batch7-multiNF-DIANN.sky.zip2025-06-30 13:55:172,85327,12832,575259,53242
TPAD_CSF4_Batch7-multiNF-DIANN-grouped.sky.zip2025-06-30 13:46:482,67226,43931,769253,11942
TPAD_CSF5_Batch8-multiNF-DIANN.sky.zip2025-06-30 13:02:062,85327,12832,575259,53254
TPAD_CSF5_Batch8-multiNF-DIANN-grouped.sky.zip2025-06-30 11:52:172,67226,43931,769253,11954
METRIC_Eclipse_PSB_All_QCs_2025-06-27_01-27-04.sky.zip2025-06-26 22:27:151666233
Exp_CSF_GPF_A_2024-05-06_21-16-47.sky.zip2025-06-25 18:12:201,8297,3787,37855,0401
2024-05 CSF LIT GPF-MSFragger-3.sky.zip2025-06-25 18:12:201,0825,0956,01940,4016
240207_gpf_2024-06-04_10-24-18.sky.zip2025-06-25 18:12:201,2886,98410,593126,0861
230305_ev2_prm_final_inj1_2024-06-04_07-32-10.sky.zip2025-06-25 18:12:207222,0892,08914,44942
230124_p2_neo_30min_3500targets_opt_trans_pepleveldilution_2024-06-04_06-58-16.sky.zip2025-06-25 18:12:201,0273,5013,50111,42041
CSF_neurod105_assay_individuals_manual_2024-06-03_15-26-36.sky.zip2025-06-25 18:12:201029029026,34537
Exp_CSF_MMCC_quant_all_adjBound_opttrans_nochick_2024-06-03_14-53-02.sky.zip2025-06-25 18:12:201,2058,3748,37424,93427
OT_GPF_PRM_survey_MMCC_boundaries_opttrans_nochick_2024-06-03_14-36-08.sky.zip2025-06-25 18:12:201,2801,9711,9715,80127
LIT_GPF_survey_newAlign_MMCC_boundaries_opttrans_nochick_2024-06-02_15-26-11.sky.zip2025-06-25 18:12:207982,0352,0355,99827
Aducanumab_Selectivity_2025-06-19_12-58-48.sky.zip2025-06-19 09:59:0644851236
hela_isolation_window_concentration_2000ng.sky.zip2025-06-02 18:36:1910,365188,947223,7653,101,14818
hela_isolation_window_experiment_200ng.sky.zip2025-06-02 18:36:1910,365188,947223,7653,101,14818
hela_isolation_window_experiment_500ng.sky.zip2025-06-02 18:36:1910,364188,947223,7653,101,14818
hela_isolation_window_experiment_1000ng.sky.zip2025-06-02 18:36:1910,365188,947223,7653,101,14818
2025-0405-MMCC-EV-Astral-noimpute_2025-05-29_11-52-05.sky.zip2025-06-02 18:36:194,90737,54742,331335,89142
2025-0405-MMCC-EV-Actis-noimpute_2025-05-29_11-46-45.sky.zip2025-06-02 18:36:195,18541,97847,810380,07242
SMTG-low-value-imputed_2025-05-01_14-22-15.sky.zip2025-06-01 21:38:1710,383187,220217,1092,214,24878
SMTG-MissForest-imputed_2025-05-01_11-41-41.sky.zip2025-06-01 20:04:5710,383187,220217,1092,214,24878
SMTG-nettle-imputed_2025-04-30_12-25-18.sky.zip2025-06-01 18:16:1410,639215,139251,4792,483,95978
SMTG-unimputed_2025-04-30_08-55-40.sky.zip2025-06-01 13:32:5610,639215,139251,4792,483,95978
TEI-REX-unimputed_2025-04-29_15-46-15.sky.zip2025-06-01 11:49:381,30749,85259,007585,98796
TEI-REX-nettle-imputed_2025-04-29_13-36-50.sky.zip2025-06-01 11:15:251,30749,85259,007585,98796
MagNet-holdout-nettle-imputed_2025-05-01_08-50-25.sky.zip2025-06-01 09:40:175,29914,11015,07460,28842
hela_isolation_window_concentration_2000ng.sky.zip2025-05-30 15:25:4610,365188,947223,7653,101,14818
ecoli_large_replicates_loaded_refined_2024-05-30_14-02-04.sky.zip2025-05-30 12:00:183669899894,9408
ecoli_large_replicates_loaded_2024-05-30_14-00-59.sky.zip2025-05-30 12:00:184611,3021,3027,5248
ecoli_large_replicates_2024-05-30_14-00-05.sky.zip2025-05-30 12:00:184611,3021,3027,5240
ecoli_subset_replicates_refined_cv_2024-05-30_13-58-18.sky.zip2025-05-30 12:00:187592,2662,26612,8072
ecoli_subset_replicates_refined_2024-05-30_13-57-25.sky.zip2025-05-30 12:00:187592,4372,43713,6022
ecoli_subset_replicates_2024-05-30_13-56-16.sky.zip2025-05-30 12:00:187592,4372,44130,8572
gpf_results_importer_2024-05-30_13-54-14.sky.zip2025-05-30 12:00:181,1925,3967,42785,6731
gpf_results_manual_2024-05-30_13-52-23.sky.zip2025-05-30 12:00:181,1925,3967,42785,6731
pq500_100spd_plasma_final_lightheavy_replicates_2024-05-30_13-50-10.sky.zip2025-05-30 11:58:415798181,62213,69910
pq500_60spd_plasma_final_lightheavy_replicates_2024-05-30_13-48-26.sky.zip2025-05-30 11:58:415798181,62213,87610
pq500_100spd_plasma_final_replicates_2024-05-30_13-47-38.sky.zip2025-05-30 11:58:415798188187,08110
pq500_60spd_plasma_final_replicates_2024-05-30_13-46-43.sky.zip2025-05-30 11:58:415798188186,97710
pq500_100spd_plasma_multireplicate_results_refined_2024-05-30_13-46-07.sky.zip2025-05-30 11:58:415798188187,0811
pq500_60spd_plasma_multireplicate_results_refined_2024-05-30_13-45-40.sky.zip2025-05-30 11:58:415798188186,9771
pq500_100spd_plasma_multireplicate_results_2024-05-30_13-45-07.sky.zip2025-05-30 11:58:415798188187,6512
pq500_60spd_plasma_multireplicate_results_2024-05-30_13-44-21.sky.zip2025-05-30 11:58:415798188187,6012
pq500_100spd_neat_multireplicate_results_refined_2024-05-30_13-43-42.sky.zip2025-05-30 11:58:415798188187,6891
pq500_60spd_neat_multireplicate_results_refined_2024-05-30_13-43-05.sky.zip2025-05-30 11:58:415798188187,6011
pq500_100spd_neat_multireplicate_results_2024-05-30_13-42-26.sky.zip2025-05-30 11:58:4157981881811,0881
pq500_60spd_neat_multireplicate_results_2024-05-30_13-41-26.sky.zip2025-05-30 11:58:4157981881811,0881
pq500_60spd_neat_multireplicate_2024-05-30_13-40-53.sky.zip2025-05-30 11:58:4157981881811,0880
hela_isolation_window_experiment_200ng.sky.zip2025-05-30 01:29:3910,365188,947223,7653,101,14818
hela_isolation_window_experiment_500ng.sky.zip2025-05-30 00:53:5310,364188,947223,7653,101,14818
hela_isolation_window_experiment_1000ng.sky.zip2025-05-29 23:15:1110,365188,947223,7653,101,14818
2025-0405-MMCC-EV-Astral-noimpute_2025-05-29_11-52-05.sky.zip2025-05-29 12:13:324,90737,54742,331335,89142
2025-0405-MMCC-EV-Actis-noimpute_2025-05-29_11-46-45.sky.zip2025-05-29 12:03:295,18541,97847,810380,07242
20240709_OBIPhA.sky.zip2025-05-16 09:25:513333723512
Swaney-IPMS-Data-DIANN_2025-05-15_11-53-43.sky.zip2025-05-15 12:02:265,18545,78152,836422,66115
Vial Comparison Post 01152025 v1 (not daily)_2025-04-29_15-52-29.sky.zip2025-04-30 21:22:2310242419
Vial Comparison Pre v2_2025-04-29_15-49-25.sky.zip2025-04-30 21:22:2310242423
ATI_Samples_2023_2025-04-26_13-39-03.sky.zip2025-04-28 10:30:1413244828042
ATI_Response_2023_2025-04-26_13-25-06.sky.zip2025-04-28 10:30:1413244828018
ATI_Samples_2022_2025-02-20_23-31-07.sky.zip2025-04-28 10:30:1012234626848
ATI_Samples_2021_2025-02-20_23-21-52.sky.zip2025-04-28 10:30:0812234626830
2023_ATIsamples_circe_2025-02-20_13-24-11.sky.zip2025-04-25 14:58:1713224325096
2022_ATIsamples_circe_2025-02-20_13-17-06.sky.zip2025-04-25 14:58:0912224325097
2021_ATIsamples_circe_2025-02-20_13-06-53.sky.zip2025-04-25 14:58:0212224325094
SICK_glyco_DIA_OrbitrapSCE_library_2025-04-19_01-42-54.sky.zip2025-04-19 17:49:212455,7962,69935,937100
SICK_glyco_DIA_AstralCE_library_2025-04-19_01-01-56.sky.zip2025-04-19 17:49:212568,9083,80054,729100
051024_PlasmaPilotwithDose_2025-04-10_16-09-16.sky.zip2025-04-10 13:09:4114848366
050124_CortexMatrixSelectivityTesting_2025-04-10_15-56-24.sky.zip2025-04-10 12:56:481485260
METRIC_Exploris_PSB_All_QCs_2025-04-10_15-22-54.sky.zip2025-04-10 12:22:09166629
Histonas_654187687vez_2025-04-10_14-40-28.sky.zip2025-04-10 05:47:5400000
MS3_15N_dilution_2025-04-04_14-57-13.sky.zip2025-04-07 04:48:0677113776051
Transition_1_Astral_Stellar_second_set_cut_off.sky.zip2025-04-07 04:48:069013,1103,57514,81722
Transition_1_Astral_Stellar_second_set.sky.zip2025-04-07 04:48:069014,7315,43722,64622
pdDiscoverer_GPF.sky.zip2025-04-07 04:48:063962,4523,54842,2186
Intermediate_1_Astral_Stellar_second_subset_CV30.sky.zip2025-04-07 04:48:064811,9972,22411,4778
Intermediate_1_Astral_Stellar_second_subset.sky.zip2025-04-07 04:48:065532,5002,82314,4028
GPF_plasma_refined_210prot.sky.zip2025-04-07 04:48:062106847394,5003
GPF_plasma_intermediate.sky.zip2025-04-07 04:48:063221,5701,90712,7529
GPF_plasma.sky.zip2025-04-07 04:48:063221,5701,90712,7529
final_assay_Astral_Stellar_410.sky.zip2025-04-07 04:48:064091,2361,3056,2443
all15N_peptides_absolute_quantification.sky.zip2025-04-07 04:48:067561124983
15N_dilution.sky.zip2025-04-07 04:48:0675711465452
Unknown-HMW-GS-Combination_2024-12-12_13-43-29.sky.zip2025-04-01 14:47:3114404039258
Known-HMW-GS-Combination_2024-12-12_13-15-23.sky.zip2025-04-01 14:47:2614404039237
07_Final-Method_Pooled-Sample_2024-12-12_13-01-40.sky.zip2025-04-01 14:47:211440403814
06_Refinement-Method_Pooled-Sample_2024-12-12_13-01-05.sky.zip2025-04-01 14:47:211467671,0164
05_Potential-Marker-Peptide_SingleRuns_2024-12-12_12-53-42.sky.zip2025-04-01 14:47:1614671343,0966
04_Present-in-positive_Single-Runs_2024-12-11_10-53-50.sky.zip2025-04-01 14:47:09141022054,5446
03_Confirmation__Pooled-Sample_2024-12-11_10-46-23.sky.zip2025-04-01 14:47:06141092194,8341
02_First-Screening_Pooled-Sample_Reduced-For-Confirmation_2024-12-11_10-39-53.sky.zip2025-04-01 14:46:56141242595,7621
01_First-Screening_Pooled-Sample_2024-12-11_10-37-06.sky.zip2025-04-01 14:46:561424561213,1531
050924withassaymapcurves_2025-04-01_15-31-03.sky.zip2025-04-01 12:31:261484862
051024_PlasmaPilotwithDose_2025-04-01_15-30-07.sky.zip2025-04-01 12:30:3114848369
benchmark_elution-evaluation_1_2024-07-24_16-47-22.sky.zip2025-03-20 11:11:23258516588548

 

Fig4C.

Cell-based kinase assay. PKC activator PMA, PKCa inhibitor Gö6976 and Akt activator IGF-1 and inhibitor MK-2206 were used to activate or block signaling pathways in C2 cells. For targeted MS analysis, phosphopeptides were enriched by Myc-tag and TiO2-based enrichment.

Figure 4D.

Immunoblot analysis of PKCα and Akt activities in C2 cells following pharmacologic interventions as indicated in 4C. Pan- and phospho-specific antibodies were used to detect total protein amounts and phosphoisoforms. GAPDH was used as loading control.

Figure 4e.

Targeted MS data of hFLNc phosphopeptides comprising the phosphorylation sites pS2233, pS2233/pS2236 and pS2236. MS data were quantified using Skyline and normalized to an internal phosphopeptide standard and the mock-treated control (DMSO). Intensities of phosphopeptides distinctive for a specific phosphorylation site in hFLNc d18-21 WT were added up per experiment and represented as normalized mean log2 ratio (treatment/control) ± SEM (n=4; *, p ≤ 0.05; **, p ≤ 0.01)

 

This data is available under the CC BY 4.0 license.